Abstract
This chapter provides a retrospective overview of the Brazilian government's adoption and use of public health Trade-Related Aspects of Intellectual Property (TRIPS) agreement safeguards to increase access to medicines in the public health system. The analysis will assume that initiatives to address patent barriers and the local production6 of medicines can have either a synergic or antagonistic effect on the reduction of the prices of monopoly medicines, depending on the approaches adopted. The patent system in Brazil plays a critical role in price increase resulting from the SUS’ procurement of brand-name lifesaving medicines because it allows companies to charge high prices, thereby limiting government's strategies for price regulation. The Brazilian delegation, which included health professionals from the National AIDS Program, attended the conference primarily to highlight the problems caused by the TRIPS Agreement, especially on prices of the patented medicines.